Biomarkers as a guide to therapy in heart failure patients
There has been much interest in the biomarker known as N-terminal brain natriuretic peptide (BNP) as a precise guide for the diagnosis, prognosis and treatment of heart failure. view more (2009-01-28)
Kidney transplant survival can be long-term for people with HIV
A Johns Hopkins study finds that HIV-positive kidney transplant recipients could have the same one-year survival rates for themselves and their donor organs as those without HIV, provided certain risk factors for transplant failure are recognized and tightly managed. view more (2009-01-20)
Glitches in DNA repair genes predict prognosis in pancreatic cancer
Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from The University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. view more (2009-01-14)
Older women less likely than men to be listed for kidney transplants
A Johns Hopkins transplant surgeon has found strong evidence that women over 45 are significantly less likely to be placed on a kidney transplant list than their equivalent male counterparts, even though women who receive a transplant stand an equal chance of survival. view more (2009-01-13)
Toxicity mechanism identified for Parkinson's disease
Neurologists have observed for decades that Lewy bodies, clumps of aggregated proteins inside cells, appear in the brains of patients with Parkinson's disease and other neurodegenerative diseases. view more (2009-01-05)
Dormant cancer cells rely on cellular self-cannibalization to survive
A single tumor-suppressing gene is a key to understanding, and perhaps killing, dormant ovarian cancer cells that persist after initial treatment only to reawaken years later, researchers at The University of Texas M. D. Anderson Cancer Center report in the December Journal of Clinical Investigation. view more (2009-01-05)
Minimizing obesity's impact on ovarian cancer survival
Obesity affects health in several ways, but new research shows obesity can have minimal impact on ovarian cancer survival. A study by researchers at the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center found ovarian cancer survival rates are the same for obese and non-obese women if their chemotherapy doses are closely matched... view more... (2008-12-29)
An ESC statement on gender differences in medical care and survival after myocardial infarction
A paper published online by the journal Circulation on 8 December 2008 concluded that, while men and women have a similar in-hospital death rate following acute myocardial infarction, women with STEMI had an adjusted mortality rate almost twice as high as men (10.2% versus 5.5%). view more (2008-12-18)
First experimental evidence for speedy adaptation to pesticides by worm species
Scientists at the Instituto Gulbenkian de Ciencia (IGC) and the Faculty of Science of the University of Lisbon, in Portugal, have shown that populations of the worm Caenhorabditis elegans become resistance to pesticides in 20 generations, that is, in only 80 days. view more (2008-12-18)
Analysis shows revlimid plus dexamethasone increases overall survival in multiple myeloma patients
Celgene International Sarl (NASDAQ: CELG) announced that data from a landmark analysis of patients with relapsed/refractory multiple myeloma found that continuous treatment with REVLIMID (lenalidomide) in combination with dexamethasone after achieving best response resulted in significantly longer overall survival and increased time to disease... view more... (2008-12-11)
Analysis shows that vidaza prolongs survival in patients with higher-risk myelodysplastic syndromes
The Myelodysplastic Syndromes (MDS) Foundation announced today that a subanalysis of the AZA-001 phase III international clinical trial shows that treatment with VIDAZA (azacitidine) can extend overall survival and reduce the risk of death in elderly higher-risk MDS patients. view more (2008-12-11)
Data presented demonstrate prolonged overall survival for patients with acute myeloid leukemia
The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with... view more... (2008-12-11)
Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. view more (2008-12-10)
Race a factor in receiving transplant treatment for bone marrow cancer but does not affect outcomes
A new study by researchers at The Medical College of Wisconsin Cancer Center Milwaukee, has found that African Americans and whites have identical survival rates after undergoing autologous (self donor) bone marrow transplant treatment for a common cancer of the bone marrow (multiple myeloma). view more (2008-12-09)
Men with wives, significant others more likely to be screened for prostate cancer
Although the link between early screening and prostate cancer survival is well established, men are less likely to go for early screening unless they have a wife or significant other living with them. view more (2008-12-08)
Preoperative radiation may improve survival rates in advanced rectal cancer patients
Patients treated with radiation prior to surgery for advanced rectal cancer have fewer instances of cancer recurrence and better overall survival rates, according to a recent Geisinger report. view more (2008-12-02)
Iressa proves just as effective as chemotherapy for lung cancer
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson... view more... (2008-11-21)
Survival of head and neck cancer patients is greatly affected by coexisting ailments
Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish... view more... (2008-11-20)
Cancer survival rates impact type of Web communities used by patients
Online support communities for high survival rate cancers contain a greater amount of emotional support content than online support communities for cancers with low survival rates, according to a new study from the University of Michigan Health System and the VA Ann Arbor Healthcare System. view more (2008-11-19)
Novel 4-drug combination proves safe for lung cancer treatment
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center. view more (2008-11-13)
|
|
